A Novel Doxorubicin Prodrug with Controllable Photolysis Activation for Cancer Chemotherapy

Author： Ibsen Stuart   Zahavy Eran   Wrasdilo Wolf   Berns Michael   Chan Michael   Esener Sadik  

Publisher： Springer Publishing Company

ISSN： 0724-8741

Source： Pharmaceutical Research, Vol.27, Iss.9, 2010-09, pp. : 1848-1860

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Doxsaliform: A Novel N-Mannich Base Prodrug of a Doxorubicin Formaldehyde Conjugate

By  

Letters in Drug Design & Discovery, Vol. 1, Iss. 3, 2004-07 ,pp. : 247-255

Bentham Science Publishers

Access to resources Recommend Favorite

Safety, Pharmacokinetics and Biodistribution Studies of a β-galactoside Prodrug of Doxorubicin for Improvement of Tumor Selective Chemotherapy

By Devalapally Harikrishna   Rajan Kombu Subramanian   Akkinepally RaghuRam Rao   Devarakonda Rama Krishna  

Drug Development and Industrial Pharmacy, Vol. 34, Iss. 8, 2008-08 ,pp. : 789-795

Informa Healthcare

Access to resources Recommend Favorite

Nanoemulsion: A Novel Eon in Cancer Chemotherapy

By  

Mini Reviews in Medicinal Chemistry, Vol. 17, Iss. 18, 2017-11 ,pp. : 1778-1792

Bentham Science Publishers

Access to resources Recommend Favorite

Evaluation of the tumor targeting of a FAPαα-based doxorubicin prodrug

By Huang Sichao   Fang Rui   Xu Jun   Qiu Shenghong   Zhang Huan   Du Jun   Cai Shaohui  

Journal of Drug Targeting, Vol. 19, Iss. 7, 2011-08 ,pp. : 487-496

Informa Healthcare

Access to resources Recommend Favorite

Prodrug strategies in cancer therapy

By Denny W.A.  

European Journal of Medicinal Chemistry, Vol. 36, Iss. 7, 2001-08 ,pp. : 577-595

Elsevier

Access to resources Recommend Favorite